Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Senior Clinical Editor
Editorial Director, Hematology/Oncology
This program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who provide care for patients with advanced ovarian cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 2.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 01, 2017, through August 31, 2018:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.
Downloadable PDF with clinical insights, approved agents, and available assays for MSI-high/MMR-deficient colorectal cancer and other solid tumors.
Downloadable PDF covering genetic risk, therapies, and testing strategies for BRCA1/2 mutations in breast, ovarian, pancreatic, and prostate cancers.
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.